This is a parallel group, multisite prospective clinical study. The purpose of this study is to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and improves coordination of care to address patient needs.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
77
ASCENT includes the following components: * Survivorship care plan created through the ASCENT tool * Online tool which assesses health care needs and facilitates receipt of care * A national-level navigator who helps the participant to access support services * Periodic reminders for the participant to pursue recommended survivorship care
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Emory University & Winship Cancer Institute
Atlanta, Georgia, United States
Johns Hopkins School of medicine & Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Abiding by the survivorship guidelines as measured by making an appointment within 6 months of enrollment OR completing a guideline-based assessment.
Abiding by the survivorship guidelines is defined as either of: Making an appointment with primary health care provider within 6 months of enrollment, OR completing a guideline-based assessment or management strategy for reducing side effects related to prostate cancer treatment.
Time frame: 6 months
Assess trial participants', caregivers'/family members', and staff satisfaction and experiences with the ASCENT technology and trial.
Focus group comments and question responses detailing trial participants', caregivers'/family members', and staff's satisfaction and experiences with ASCENT.
Time frame: 6 months
General health status
General health status will be measured using the EuroQol five dimensions questionnaire (EQ-5D).
Time frame: 6 months
Existence and severity of depression
Existence and severity of depression will be evaluated using the Patient Health Questionnaire (PHQ-9).
Time frame: 6 months
Prostate-cancer specific quality of life.
Prostate-cancer specific quality of life will be determined using the Expanded Prostate Cancer Index Composite - Short Form (EPIC-26).
Time frame: 6 months
Overall health-related-quality of life including, but not limited to, mental and physical functioning as measured by the Short Form Health Survey
Overall health-related-quality of life will be measured using the Short Form Health Survey (SF-12).
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UNC Lineberger Cancer Center
Chapel Hill, North Carolina, United States
Duke Cancer Institute
Durham, North Carolina, United States